Zhengye Biotechnology Holding Limited

What they do

The company operates through No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China, and describes itself as a biotechnology holding company with GMP and GSP references in its filing. It is incorporated in the Cayman Islands and its Class A Ordinary Shares trade on the Nasdaq Stock Market under the symbol ZYBT. The filing states employees are engaged in manufacturing under Good Manufacturing Practice and distribution under Good Supplying Practice. The current disclosure does not identify specific vaccine products or customer names.

Revenue drivers

• Core product sales (unnamed in filing) — The company is classified under Pharmaceutical Preparations (SIC) and operates as a biotechnology company holding GMP and GSP qualifications, indicating revenue from sales of regulated pharmaceutical products, but the excerpt does not name the products or quantify their contribution.
• China domestic market — The excerpt does not break out revenue by geography, but all disclosed operations are located in Jilin City, Jilin Province, China, and the filing defines China/PRC excluding Taiwan, indicating the business is China-centric.
• Product categories — No product-level revenue split is disclosed in the excerpt; the filing's stated SIC code places the company within the pharmaceutical preparations industry.

Recent performance

Revenue fell to $16.6 million in 2025 from $25.5 million in 2024. Net income swung to a net loss of $10.0 million in 2025 from net income of $1.6 million in 2024. Operating cash flow declined to $1.9 million in 2025 from $5.6 million in 2024. Diluted EPS was reported at $0.03 for 2024, with no diluted EPS figure provided for 2025 in the excerpt. At December 31, 2025, total assets were $62.4 million, total liabilities $18.6 million, and shareholder equity $35.7 million.

Strategy

The excerpt provided does not describe specific strategic initiatives, planned investments, or product pipeline priorities. The filing's substantive MD&A narrative is largely absent from the excerpt, which includes only the table of contents and introductory definitions for the Form 20-F. The only forward-looking structural change disclosed is the reclassification of ordinary shares into Class A and Class B Ordinary Shares effective March 24, 2026, creating a dual-class share structure, with 47,391,376 ordinary shares outstanding as of December 31, 2025.

Risks

• Revenue decline — Revenue fell 34.9% in 2025 to $16.6 million from $25.5 million, indicating contraction in the company's core business.
• Swing to substantial net loss — The company moved from $1.6 million of net income in 2024 to a $10.0 million net loss in 2025, raising questions about cost structure and margins that the excerpt does not explain.
• Cash generation deterioration — Operating cash flow fell to $1.9 million in 2025 from $5.6 million in 2024, which is a material reduction in internally generated liquidity.
• Dividend history anomaly — Disclosed dividends per share of $17,712,000 in 2022, $55,104,000 in 2023, and $205,000 in 2024 appear inconsistent with reported net income and share counts, and the excerpt does not reconcile them.

Outlook

The excerpt does not contain management's forward-looking statements on revenue, earnings, or product development. The only explicitly forward-looking disclosure is the post-year-end reclassification of shares into a dual-class structure effective March 24, 2026. No guidance, capital expenditure plans, or pipeline timelines are provided in the source material.